REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC market research report, Cell-Based Assays: Technologies and Global Markets, provides a detailed overview and thorough analysis of the present and future global market for cell-based techniques. This report analyzes in detail the cell-based assays available and currently used and their markets. This report includes products in this market and detailed analyses of markets and competitive environments, cell assays markets in newly emerging regions, and instrumentation and robotics and their impact on the market. The report includes information about significant products and assays, key players, issues and trends, current market status of cell-based assays, strengths, weaknesses, opportunities, and threats facing various assays and developments already on the market, major issues involved in the research and development (R&D) of more effective cell-based approaches, for drug discovery, and absorption, distribution, metabolism, and excretion (ADME)/ toxicity assays in development and in use.
REASONS FOR DOING THE STUDY
Cell-Based assays have emerged as a more relevant alternative to biochemical assays involving the use of purified proteins. Witnessing the growth in demand for cell-Based assays, a number of cell culture and liquid-handling instruments available on the market now allow cell-based screening. The majority of compound screening programs performed by the biopharmaceutical industry rely on cell-based assays for functional measures of target activation. Label-free cellular assays are driving this paradigm forward, with their sensitivity, robustness, ease of use, and flexibility. These assays are now performed routinely throughout early drug discovery from target identification and validation to primary screening, lead identification, and lead optimization and into safety and toxicology. There is a need to understand the trends in this market, currently available assays, and latest developments for drug discovery.
SCOPE OF REPORT
The proposed report will give an update on Cell-Based Assays: Technologies and Global Markets. It will review global markets for cell-based assays and new developments and will forecast trends for use of these assays for drug discovery and safety and toxicology through 2015. Important assays, technologies and latest developments, market share by assay type, products on the market and market share by company, and statistical information for types of cancers prevalent worldwide, with special emphasis on the U.S. market. The report also includes current issues and trends affecting the industry and costs, and factors influencing demand will be discussed. The report covers products in development, new technologies, trends, alliances, and mergers. The report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints, and opportunities.
INTENDED AUDIENCE
This report is an exhaustive study on the worldwide cell-based assays market, giving crucial statistics and analysis on existing technologies, latest trends, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This report may prove crucial for the firms or investors seeking investments in the concerned sector. This report shows cell-based assays currently being used, new developments, spending trends, and revenue prospects for cell-based assays in pharma. The report provides market data for 2009 to 2015 and also covers commercial prospects for cell assays in drug research and ADME/toxicity assays.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news, and developments and through access to paid databases. The base year of the report is 2009, with forecast data provided through 2015. Historical, base year and forecast data are provided for each market segment of this report. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D, and current product growth, etc.
ANALYST CREDENTIALS
Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of preclinical, alliance management, discovery, and technology development and marketing experience. Her strong focus areas include oncology and cardiovascular diseases, with expertise in molecular and cell biology and complex cell-based biological assays ranging from drug discovery, in vitro and in vivo screening, in vivo model development, and pharmacokinetics. She has experience working with early start-ups.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers.
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The authors assume no responsibility for any loss or damage that might result from reliance on the reported information or its use.
